Latest From Prasco Laboratories
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."
Prasco has launched an authorized generic version of NuvaRing in the US, hot on the heels of Amneal’s launch of the first FDA-approved generic.
Advisory committee will re-evaluate the continued marketing of AMAG Pharmaceuticals’ preterm birth drug after a failed confirmatory study; the last time an advisory committee weighed in on the future of an accelerated approval drug was for Avastin's breast cancer claim.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Prasco Laboratories
- Senior Management
Christopher Arington, CEO
David Furniss, CFO
David R Vucurevich, Pres. & COO
- Contact Info
Phone: (513) 618-3333
6125 Commerce Ct.
Mason, OH 45040
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.